Company: PRME
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050422
Chunk: 23

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
AccumulatedDeficitTotalStockholders’Equity(in thousands, except share amounts)SharesAmountBalance as of December 31, 202397,377,121 $2 $624,414 $(15)$(491,330)$133,071 Issuance of common stock from public offering, net of issuance costs of $8.9 million22,560,001 — 132,055 — — 132,055 Issuance of pre-funded warrants, net of issuance costs of $1.2 million— — 18,800 — — 18,800 Issuance of common stock under the employee stock purchase plan74,488 — 436 — — 436 Issuance of common stock upon exercise of stock options9,664 — 36 — — 36 Stock-based compensation expense— — 5,209 — — 5,209 Change in unrealized loss on investments, net of tax— — — (80)— (80)Net loss— — — — (45,761)(45,761)Balance as of March 31, 2024120,021,274 2 780,950 (95)(537,091)243,766 Issuance of common stock upon exercise of stock options9,539 — 35 — — 35 Stock-based compensation expense— — 8,091 — — 8,091 Change in unrealized loss on investments, net of tax— — — 24 — 24 Net loss— — — — (55,327)(55,327)Balance as of June 30, 2024120,030,813 $2 $789,076 $(71)$(592,418)$196,589 Issue of common stock under the Securities Purchase Agreement to BMS — related party11,006,163 — 38,081 — — 38,081 Issuance of common stock under the employee stock purchase plan115,021 — 401 — — 401 Issuance of common stock upon exercise of stock options8,845 — 32 — — 32 Stock-based compensation expense— — 6,827 — — 6,827 Change in unrealized loss